Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in obstructive hypertrophic cardiomyopathy (Phase II)
CTR20242353Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Sende. Started Aug 2024; status: active.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on CTR20242353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242353.